Supplementary Figure S7 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants

Read full text Summarise with VIRAT
Authors: Carlos E. Stahlhut, Anna E. Maciag, Kyle A. Sullivan, Kanchan Singh, Nadege Gitego, Zuhui Zhang, Albert H. Chan, Alok Kumar Sharma, Patrick Alexander, Jin Shu, Yue Yang, Megan Rigby
+24 more Roger Ma, Saman Setoodeh, Brian K. Smith, Jun Pei, Dana Rabara, Erik K. Larsen, David M. Turner, Cathy Zhang, Cindy Feng, Siyu Feng, James P. Stice, Rui Xu, Kenneth Lin, Andrew G. Stephen, Felice C. Lightstone, Chunmei Ji, Keshi Wang, Dhirendra K. Simanshu, Dwight V. Nissley, Eli M. Wallace, Bin Wang, Kerstin W. Sinkevicius, Frank P. McCormick, Pedro J. Beltran
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Supplementary Figure S7 shows the dose- and time-dependent inhibition of DUSP6 and pERK in KRAS-mutant CDX models treated with BBO-11818, as well as the mean body weight in a KRASG12D CDX model treated with BBO-11818.

Fields of Study & Subjects

Protein Kinase Regulation and GTPase Signaling Melanoma and MAPK Pathways Protein Tyrosine Phosphatases

Publication details

Publication date
1 April 2026
Language
EN